Case Study Archives - Reconcile® (fluoxetine hydrochloride)

Product
Details
BOND^® Training
Information
Prescribing
Information
FAQ
Behavior
Bits

Product Details
BOND^® Training Information
Prescribing Information
FAQ
Behavior Bits

Case Study

Lola’s Story

Puddin’s Story

Search

Recent Posts

NEW! – Treating separation related problems in dogs
NEW! – Four facts about separation anxiety you probably didn’t know
NEW! – Behavior myth busting with Dr. Lisa Radosta – 2
NEW! – Behavior myth busting with Dr. Lisa Radosta – 1
How to use a Mutt Mat for behavior modification training

IMPORTANT SAFETY INFORMATION: The most common adverse events reported in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation. Reconcile chewable tablets are contraindicated for dogs with a history of seizures or when used with MAOIs. For product label, including complete safety information, see package insert.

The information, tools and material presented on this site are provided for informational and educational purposes only. Please consult your veterinarian for an official diagnosis of canine separation anxiety and to learn more about Reconcile. Click here to read the complete terms and conditions regarding use of this website.

PRN^® and Reconcile^® are registered trademarks of Pegasus Laboratories, Inc.

© PRN is a registered trademark of Pegasus Laboratories, Inc.